logo

PharmaPoint: Macular Edema-Global Drug Forecast and Market Analysis to 2026

Region:Global

Product Code:GDHC157PIDR

Download Sample Report
Published On

January 2017

Total pages

258

About the Report

PharmaPoint: Macular Edema-Global Drug Forecast and Market Analysis to 2026

Summary

Macular Edema (ME) is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. The occurrence of ME is highly frequent in diabetics and usually manifests itself as DME, a complication of diabetic retinopathy, and is the most common cause of vision loss in patients affected by diabetes mellitus. In addition the risk for ME is also higher in patients with retinal vein occlusion, a common condition in the elderly, which consists of two types: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

The current standard of care for macular edema focuses around the use of anti-VEGF therapies which are administered as intravitreal injections. There are currently two approved anti-VEGF therapies on the market for the treatment of both DME and ME-RVO, Roche/Novartis' Lucentis and Regeneron/Bayer's Eylea. Roche's oncology anti-VEGF is also used off-label in many markets. Although anti-VEGF therapies represent an effective treatment for ME, many patients do not show an adequate response to such therapy. In the case of these patients, they are often moved onto second-line treatment with corticosteroids. Over the next ten years, GlobalData forecasts four novel therapies to enter the ME market: CLS-TA, Abicipar pegol, Luminate and Optina.

GlobalData estimates that drug sales for ME in 2016 were approximately $3.7 billion across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $7.0 billion at a CAGR of 6.7%. This growth will be driven by increased uptake of market leading therapy, Eylea, increased prevalence of diabetes and improved diagnosis and treatment rates. The launch of pipeline therapies will also be a driver of growth, with Allegro's Luminate and Allergan's Abicipar pegol forecast to be the highest selling pipeline agents in 2026.

Scope

Overview of macular edema, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized macular edema therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (DME, ME-BRVO and ME-CRVO) forecast from 2016 to 2026.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the macular edema therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for macular edema therapy. The most promising candidates in Phase III development are profiled.

Analysis of the current and future market competition in the global macular edema therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to-

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global macular edema therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global macular edema therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Scope of the Report

Companies

Roche/Genentech

Novartis

Regeneron

Bayer

Santen

Allergan

Alimera Sciences

Clearside BioMedical

Allegro Ophthalmics

Table of Contents

1 Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Significant Growth Expected in the ME Market from 2016 to 2026

2.2 Eylea Will Dominate the ME Market Through to 2025

2.3 Future Players Are Unlikely to Rival the Might of Regeneron

2.4 Despite the Availability of Anti-VEGFs, Unmet Needs Remain

2.5 Late-Stage Pipeline Therapies Will Be a Driver of Growth, Especially in the US

2.6 What Do Physicians think?

3 Introduction

3.1 Catalyst

3.2 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 DME

4.1.2 ME-RVO

4.2 Classification

4.2.1 DME

4.2.2 ME-RVO

4.3 Symptoms and Diagnosis

4.3.1 DME

4.3.2 ME-RVO

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Macular Edema (2016-2026)

5.5.1 Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population

5.5.2 Age-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population

5.5.3 Sex-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population

5.5.4 Diagnosed Prevalent Cases of Clinically Significant DME Among the Diagnosed the DME Population

5.5.5 Total Prevalent Cases of ME following BRVO

5.5.6 Age-Specific Total Prevalent Cases of ME Following BRVO

5.5.7 Sex-Specific Total Prevalent Cases of ME Following BRVO

5.5.8 Total Prevalent Cases of ME Following CRVO

5.5.9 Age-Specific Total Prevalent Cases of ME Following CRVO

5.5.10 Sex-Specific Total Prevalent Cases of ME Following CRVO

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis Overview

6.2 Treatment Overview

6.2.1 Treatment Guidelines and Leading Prescribed Drugs

6.2.2 Clinical Practice

6.3 US

6.4 France

6.5 Germany

6.6 Italy

6.7 Spain

6.8 UK

6.9 Japan

7 Competitive Assessment

7.1 Overview

7.2 Product Profiles-Anti-VEGF Therapies

7.2.1 Lucentis (Ranibizumab)

7.2.2 Eylea (Aflibercept)

7.2.3 Avastin (Bevacizumab)

7.3 Corticosteroid Implants

7.3.1 Ozurdex (Dexamethasone Acetate)

7.3.2 Iluvien (Fluocinolone Acetonide)

8 Unmet Need and Opportunity

8.1 Overview

8.2 More Efficacious First-Line Therapies

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Longer Duration of Action

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Alternative Route of Administration

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Clinical Trial Mapping

9.3 Promising Drugs in Clinical Development

9.3.1 CLS-TA (Triamcinolone Acetonide)

9.3.2 Abicipar Pegol

9.3.3 Luminate (ALG-1001)

9.3.4 Optina (Danazol)

9.4 Promising Drugs in Early-Stage Development

9.4.1 REGN910-3 (Nesvacumab + Aflibercept)

9.4.2 RG-7716

9.4.3 AKB-9778

9.4.4 Brolucizumab (RTH258)

9.5 Other Drugs in Development

9.6 Biosimilars

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 Roche/Genentech

10.3.2 Novartis

10.3.3 Regeneron

10.3.4 Bayer

10.3.5 Santen

10.3.6 Allergan

10.3.7 Alimera Sciences

10.3.8 Clearside BioMedical

10.3.9 Allegro Ophthalmics

11 Market Outlook

11.1 Global Market

11.1.1 Forecast

11.1.2 Drivers and Barriers-Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research-KOLs Interviewed for this Report

12.5 Primary Research-Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Research Methodology

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022